ClinicalTrials.gg
CompletedNCT07150845Updated Oct 5, 2026

Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

A Phase 2 interventional study of EVO756 and EVO756 in Atopic Dermatitis, sponsored by Evommune, Inc.. Completed at 29 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Evommune, Inc. · Phase 2, Interventional, and Treatment

Updated Oct 2, 2026Now CompletedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Enrollment
239th of 544
121 · median 96
Started
2025
with 40 others
Phase 2
202 of 639
18 open now
Registered
599th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 239th largest by enrollment of the 544 interventional ones that give a count, is one of 41 that started in 2025, is one of 202 in phase 2, and was the 599th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • atopic dermatitis
  • eczema
  • itch
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic AD that has been present for ≥6 months
  • Validated-Investigator's Global Assessment score of ≥3
  • EASI of ≥16
  • BSA of AD involvement of ≥10%

Exclusion criteria

Exclusion Criteria:

  • Any abnormality in laboratory evaluations, physical examinations, vital signs, or at Screening
  • Use of certain medications
  • Presence of skin comorbidities or other condition(s) that may interfere with study assessments
  • Significant AD flare, in the opinion of the Investigator, within 4 weeks prior to study entry
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    Dose 1

    Orally administered EVO756, Dose 1

    Drug: EVO756

  • Experimental
    Dose 2

    Orally administered EVO756, Dose 2

    Drug: EVO756

  • Experimental
    Dose 3

    Orally administered EVO756, Dose 3

    Drug: EVO756

  • Placebo comparator
    Placebo

    Placebo control

    Drug: Placebo control

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage change in Eczema Area and Severity Index (EASI) from Baseline

    Time frame: Week 12

Secondary outcomes

  1. Percentage change in EASI from Baseline

    Time frame: Weeks 2, 4, and 8

  2. Mean changes in EASI from Baseline

    Time frame: Week 2, 4, 8, and 12

  3. Proportion of subjects with EASI-50, EASI-75, and EASI-90 from Baseline

    Time frame: Weeks 2, 4, 8, and 12

  4. Mean and absolute changes in validated Investigator Global Assessment (vIGA) score from Baseline

    Time frame: Weeks 2, 4, 8, and 12

  5. Proportion of subjects achieving a vIGA score of 0,1 with at least a 2-point reduction from Baseline

    Time frame: Weeks 2, 4, 8, and 12

  6. Mean and percentage change from Baseline in the pruritus-NRS score

    Time frame: Weeks 2, 4, 8, and 12

  7. Proportion of subjects achieving a 4-pt reduction in the pruritus-NRS score from Baseline

    Time frame: Week 2, 4, 8, and 12

  8. Mean and percentage changes from Baseline in Body Surface Area (BSA) of affected area

    Time frame: Weeks 2, 4, 8, and 12

  9. Occurrence of treatment emergent adverse events (TEAE) and serious adverse events (SAE)

    Time frame: through Week 14

07

Study locations

29 sites
  • Saguaro Dermatology
    Phoenix, Arizona 85008, United States
  • Center for Dermatology Clinical Research
    Fremont, California 94538, United States
  • Metropolis Dermatology - Downtown Los Angeles
    Los Angeles, California 90017, United States
  • Skin and Beauty Center
    Pasadena, California 91105, United States
  • Skin Care Research, LLC
    Boca Raton, Florida 33486, United States
  • Driven Research, LLC
    Coral Gables, Florida 33134, United States
  • Skin Care Research - Hollywood Dermatology
    Hollywood, Florida 33021, United States
  • TrueBlue Clinical Research
    Tampa, Florida 33609, United States
  • DS Research
    Clarksville, Indiana 47129, United States
  • Equity Medical
    Bowling Green, Kentucky 42104, United States
  • Aesthetic and Dermatology Center
    Rockville, Maryland 20850, United States
  • Great Lakes Research Group, Inc.
    Bay City, Michigan 48706, United States
  • Revival Research Institute, LLC
    Troy, Michigan 48084, United States
  • Michigan Dermatology Institute
    Waterford, Michigan 48328, United States
  • MediSearch Clinical Trials
    Saint Joseph, Missouri 64507, United States
  • Empire Dermatology
    East Syracuse, New York 13057, United States
  • Equity Medical
    New York, New York 10023, United States
  • Skin Search of Rochester, Inc.
    Rochester, New York 14623, United States
  • Wilmington Dermatology Center
    Wilmington, North Carolina 28405, United States
  • DOCS Dermatology Clinical Research
    Canal Winchester, Ohio 43110, United States
  • International Clinical Research - Murfreesboro
    Murfreesboro, Tennessee 37130, United States
  • Stryde Research
    Lewisville, Texas 75056, United States
  • Progressive Clinical Research
    San Antonio, Texas 78213, United States
  • Jordan Valley Dermatology Center
    South Jordan, Utah 84095, United States
  • Pacific Clinical Research Network (PCRN) - Christchurch
    Christchurch Central City, Christchurch 8013, New Zealand
  • Optimal Clinical Trials
    Auckland, NZL 1010, New Zealand
  • Optimal Clinical Trials
    Auckland, NZL 632, New Zealand
  • Clinical Trials NZ Limited
    Hamilton, NZL 3204, New Zealand
  • Momentum Clinical Research Lower Hutt
    Lower Hutt, NZL 5010, New Zealand
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Jul 2026, 10 months.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 10 months is below that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

Completion moved once since we started tracking on Sep 25, 2026: Jul 2026 → Aug 2026, on Oct 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2025
First posted
Sep 2, 2025
StartActual
Aug 26, 2025
Primary completionActual
Jul 23, 2026
CompletionActual
Aug 3, 2026was Jul 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 2, 2026
Study completion
Jul 2026→Aug 3, 2026 (actual)
Oct 2, 2026
Enrollment
120 (estimated)→121 (actual)
Oct 2, 2026
Show all 2 updates
  1. Oct 5, 2026
    Minor edits only
    + 1 other change: conditions
  2. Oct 2, 2026
    Active, not recruiting→Completed
    Study completion Jul 2026→Aug 3, 2026 (now actual)
    Enrollment 120 (estimated)→121 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07150845
Lead sponsor
Evommune, Inc.
Responsible party
Sponsor
First posted
Sep 2, 2025
Start date
Aug 26, 2025
Primary completion
Jul 23, 2026
Completion
Aug 3, 2026
Last update
Oct 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EVO756

Start the discussion